2,625 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Pasadena Private Wealth LLC

Pasadena Private Wealth LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGNFree Report) during the second quarter, HoldingsChannel reports. The fund acquired 2,625 shares of the medical research company’s stock, valued at approximately $583,000.

Several other large investors have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its holdings in shares of Amgen by 83,875.6% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Norges Bank acquired a new stake in shares of Amgen during the 4th quarter worth $1,351,778,000. Envestnet Asset Management Inc. increased its position in shares of Amgen by 216.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,690,718 shares of the medical research company’s stock worth $228,997,000 after purchasing an additional 1,839,455 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after purchasing an additional 1,806,456 shares in the last quarter. Finally, Morgan Stanley lifted its position in Amgen by 12.9% during the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Institutional investors own 74.44% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AMGN. Credit Suisse Group dropped their target price on shares of Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Mizuho upped their target price on Amgen from $214.00 to $223.00 and gave the stock a “neutral” rating in a research note on Monday, August 14th. Barclays decreased their price target on Amgen from $225.00 to $210.00 in a research note on Tuesday, July 11th. Argus upped their price objective on Amgen from $260.00 to $280.00 in a research report on Monday. Finally, Oppenheimer reiterated an “outperform” rating and issued a $280.00 target price on shares of Amgen in a research report on Tuesday, July 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $265.44.

View Our Latest Report on AMGN

Insiders Place Their Bets

In related news, EVP Murdo Gordon sold 9,558 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $262.43, for a total transaction of $2,508,305.94. Following the sale, the executive vice president now owns 44,308 shares in the company, valued at approximately $11,627,748.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

Amgen Trading Up 1.2 %

Shares of AMGN stock traded up $3.23 on Monday, hitting $263.95. The company had a trading volume of 531,096 shares, compared to its average volume of 2,452,225. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $296.67. The company has a debt-to-equity ratio of 8.76, a quick ratio of 2.48 and a current ratio of 2.77. The firm has a market cap of $141.19 billion, a P/E ratio of 17.80, a P/E/G ratio of 3.30 and a beta of 0.61. The stock’s 50-day moving average is $248.12 and its two-hundred day moving average is $237.72.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share for the quarter, beating analysts’ consensus estimates of $4.44 by $0.56. The business had revenue of $7 billion during the quarter, compared to the consensus estimate of $6.66 billion. Amgen had a net margin of 30.02% and a return on equity of 196.60%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.65 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 18.35 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Friday, August 18th were given a dividend of $2.13 per share. The ex-dividend date was Thursday, August 17th. This represents a $8.52 dividend on an annualized basis and a yield of 3.23%. Amgen’s dividend payout ratio (DPR) is currently 57.45%.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.